Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
A phase 2/3 trial of Umbralisib and Venetoclax in Chronic lymphocytic leukaemia, run by TG Therapeutics, Inc., recorded as terminated on the registry.
Overview
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) is a phase 2/3 interventional study registered as NCT03801525 by TG Therapeutics, Inc., with 277 participants recorded, started 2019-05-16 and due to reach its primary completion in 2022-12-20. Interventions recorded: Ublituximab, Umbralisib, Venetoclax. Conditions recorded: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.
Linked to the drug Umbralisib because the registry names it among its interventions and Chronic lymphocytic leukaemia among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialAcalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Shares Umbralisib, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialStudy to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Shares Umbralisib and the tag pipeline.
- TrialStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialA Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
- TrialPhase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.